WednesdayJul 20, 2022 10:31 am

Study Reveals Proteins That Can Trigger Immune System Malfunction

At least 20 million Americans live with autoimmune disorders, but there’s still much we don’t know about these conditions. The disorders usually occur when, for some reason, the immune system goes haywire and begins to attack healthy tissue. In addition to not knowing exactly what causes autoimmune disorders, we still haven’t figured out a way to cure them. Recently, however, researchers studying immune disorders discovered a novel method of triggering the immune system via certain proteins. This discovery could provide scientists with the chance to know more about autoimmune conditions such as lupus and scleroderma. Investigators from Weill Cornell Medicine…

Continue Reading

WednesdayJul 20, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Responds to Growing Concerns About Concussion Head Injuries with Drug Device in Clinical Trial

As awareness of the long-term hazards of concussive head injuries for young athletes has increased during the past decade, advocates and business enterprises have stepped up to improve coach responsiveness to players’ condition While efforts primarily focus on assessing injury, Odyssey Health Inc. is developing a product it hopes to become the first drug device with FDA approval for treating a concussed patient after injury Odyssey is enrolling patients in a Phase 1 human clinical trial after completing pre-clinical studies in laboratory animals The medical research company’s assets include treatments for patients who may have undiagnosed heart disease, patients choking…

Continue Reading

TuesdayJul 19, 2022 12:46 pm

Study Highlights New Insights on Neurological Autoimmune Illnesses

UT Southwestern researchers recently reported that they had used cryoelectron microscopy to obtain the image of an auto-antibody that had bound itself to the surface receptor of a nerve cell. This discovery shows the mechanism behind neurological autoimmune illnesses and may be useful in the development of novel therapies for autoimmune diseases. Autoimmune illnesses are disorders that cause an individual’s immune system to mistakenly attack their body. These illnesses reduce the body’s ability to fight germs such as viruses and bacteria, which in turn, makes individuals susceptible to infections. Common autoimmune illnesses include systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis,…

Continue Reading

TuesdayJul 19, 2022 9:45 am

QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial

Treating patients with primary or secondary bone cancer remains goal, says company CEO Radiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cells QSAM is working to develop CycloSam(R) as a breakthrough therapeutic for adult and pediatric bone cancer patients QSAM Biosciences (OTCQB: QSAM), a company developing a new class of drugs called radiopharmaceuticals, is leading the charge to evaluate a new treatment for bone cancer and other related, underserved diseases. The company’s pioneering efforts are evident as the first patient has completed treatment in the company’s clinical trial designed to study the effect of its…

Continue Reading

MondayJul 18, 2022 9:53 am

Preclinical Study Uncovers Potential Key to Treating Deadly Brain Tumors

A new study has found an alternative approach that would make immunotherapy treatments more effective when treating brain tumors. Immunotherapy drugs are usually used to treat a range of cancers. However, glioblastoma multiforme, which is a fatal type of cancer, remains resistant to this revolutionary treatment because the immune system finds it hard to detect and target these tumors, allowing them to grow undisturbed. Researchers have been looking for ways to treat this deadly cancer whose tumors are usually hidden behind the blood-brain barrier. This location hinders drugs from crossing into the central nervous system’s fluid. For their research, the…

Continue Reading

FridayJul 15, 2022 11:02 am

Scientists Identify Gene Behind Pediatric Bone Cancer

Scientists at the Lineberger Comprehensive Cancer Center, University of North Carolina have found that the OTUD7A gene impacts Ewing sarcoma development. Ewing sarcoma is a type of cancer that develops primarily in children and affects bones or tissues surrounding the bones. Figures show that roughly 250 young adults and children are diagnosed with this rare cancer annually in the United States. Of this number, about one-half eventually succumb to the illness, which points to the need for better treatments. The researchers, who collaborated with Atomwise Inc. on this study, published their findings in the “Advanced Science” journal. Pengda Liu, co-lead…

Continue Reading

ThursdayJul 14, 2022 11:30 am

Study Maps How Brain Changes During Treatment for Depression

New research has mapped how an individual’s brain changes as they undergo treatment for depression. The study, which was carried out by scientists from the University of British Columbia, was focused on finding out what happened in the brain when a person underwent repetitive transcranial magnetic stimulation. This noninvasive treatment uses magnetic fields to stimulate nerve cells in an individual’s dorso-lateral prefrontal cortex. This region of the brain is involved in mood regulation. This particular treatment is usually administered when other treatment strategies, such as drugs, haven’t effectively helped a patient manage their depression. Various studies have found that antidepressants…

Continue Reading

WednesdayJul 13, 2022 3:02 pm

Online Companies Offering Mental Health Services Come Under Spotlight

The need for therapists in the United States is currently at an all-time high, with the latest data from the CDC showing about 40% of adults in the country are struggling to find help for their substance abuse or mental health issues because of a therapist shortage. With no physical providers of the services they seek nearby, most are turning to online sources to meet their needs. Numerous digital mental health companies, such as BetterHelp, which offers access to therapy sessions, have been launched these last few years. These companies often receive backing from venture capital firms and provide a…

Continue Reading

WednesdayJul 13, 2022 9:00 am

Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs

Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). The ability to target inflamed tissue (while bypassing healthy organs) suggests joint-homing peptides could deliver therapeutics or fusion imaging nanoparticles to specific diseased tissues. Better imaging, lower radiation and precision, targeted dosing could enhance the therapeutic effect of current and future therapeutics and…

Continue Reading

TuesdayJul 12, 2022 3:40 pm

Study Finds That Sex, Ethnicity May Impact Risk of Suicide After Concussion

Traumatic brain injuries are among the most difficult injuries to recover from. On top of causing issues such as speech difficulties and problems with logic, studies have found that individuals who sustain long-lasting symptoms from their injuries are more likely to develop mental health problems, including  post-traumatic stress disorder (PTSD), depression and suicidal thoughts. Up to 30% of those who survive brain injuries go on to develop post-concussion syndrome, a condition that refers to long-term symptoms after a concussion. Common symptoms of post-concussive syndrome include headaches, brain fog, nausea, blurry vision and memory problems. An estimated 80% of concussion patients…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000